Aurinia gets two new assets in acquisition, licensing deal; Shorla preps T-cell leukemia drug for commercialization
Aurinia has acquired two new pipeline assets through a buyout and research collaboration, the Canadian biotech announced Tuesday.
The first new compound comes from Thunderbolt Pharma, which Aurinia acquired in an all-stock deal. Aurinia’s new program is a recombinant Fc fusion protein designed to specifically block B-cell Activating Factor, known as BAFF, and A Proliferation-Inducing Ligand, known as APRIL. The biotech hopes the program can treat autoimmune and nephrology conditions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.